Pfizer History & Founding Timeline

Pfizer significantly overestimated sustained COVID vaccine and antiviral demand in 2022–2023, building inventory levels that required approximately $5.6 billion in write-downs when actual demand proved far lower than contracted government volumes. The inventory impairment was the single largest contributor to the collapse in reported 2023 net income and reflected modeling assumptions that did not adequately account for vaccination saturation speed.

The 2015 announcement of a merger with Allergan (structured as a tax inversion to relocate Pfizer's headquarters to Ireland) was abandoned in 2016 after the US Treasury Department changed inversion rules, costing Pfizer approximately $400 million in termination fees and diverting management attention for over a year. The episode reflected aggressive tax optimization strategy without adequate regulatory risk assessment.

Despite years of advance notice of Lipitor's 2011 patent expiry — which cost Pfizer approximately $9 billion in revenues within 12 months of generic entry — the company did not build sufficient pipeline replacement revenue to prevent the sharp earnings decline that followed. The response (Wyeth acquisition) was strategically sound but years later than optimal, reflecting inadequate long-range pipeline management.

Pfizer retained its consumer healthcare business (Advil, Centrum, ChapStick) longer than strategic logic warranted, through multiple restructurings and eventual joint venture with GSK's consumer division, before ultimately receiving Haleon shares in 2022. The multi-decade holding of a low-growth, capital-consuming business diverted resources from pharmaceutical R&D investment during critical pipeline-building periods.